



KCCO Tanzania
P.O. Box 2254 | Moshi, Tanzania

KCCO International
Division of Ophthalmology
H53 OMB, Groote Schuur Hospital
Observatory, 7925, South Africa

www.kcco.net

UGANDA

Articles on Eye Care or Ophthalmology [1995 - 2017]

Blindness surveys

1. Kamali A, Whitworth JA, Ruberantwari A, Mulwanvi F, Acakara M, Dolin P, Jonhoson G. Causes and prevalence of non-vision impairing ocular conditions among a rural adult population in SW Uganda. *Ophthalmic Epidemiol.* 1999;6:41-8.
2. Kawuma M. Eye diseases and blindness in Adjumani refugee settlement camps, Uganda. *East Afr Med J.* 2000; 77:580-2.
3. Mbulaiteye SM, Reeves BC, Karabalinde A, Ruberantwari A, Mulwany F, Whitworth JA, Johnson GJ. Evaluation of E-optotypes as a screening test and the prevalence and causes of visual loss in a rural population in SW Uganda. *Ophthalmic Epidemiol.* 2002; 9:251-62.
4. Mbulaiteye SM, Reeves BC, Mulwany F, Whitworth JA, Johnson G. Incidence of visual loss in rural southwest Uganda. *Br J Ophthalmol.* 2003;87:829-33.

Cataract

5. Courtright P, Ndegwa L, Msosa J, Banzi J. Use of our existing eye care human resources: assessment of the productivity of cataract surgeons trained in eastern Africa. *Arch Ophthalmol.* 2007;125(5):684-7.
6. Kagame K. Cataract surgery. *Community Eye Health.* 2001;14(40):71.
7. Mshangila B, Paddy M, Kajumbula H, Ateenyi-Agaba C, Kahwa B, Seni J. External ocular surface bacterial isolates and their antimicrobial susceptibility patterns among pre-operative cataract patients at Mulago National Hospital in Kampala, Uganda. *BMC Ophthalmol.* 2013 Nov 15;13:71.
8. Waddell KM, Reeves BC, Johnson GJ. A comparison of anterior and posterior chamber lenses after cataract extraction in rural Africa: a within patient randomized trial. *Br J Ophthalmol.* 2004; 88:737-9.

Childhood Blindness

9. Duncan B, Canfield L, Barber B, Greivenkamp J, Oriokot FO, Naluyinda E. The Night Vision Threshold Test (NVTT): a simple instrument for testing dark adaptation in young children. *J Trop Pediatr.* 2000; 46: 30-5.
10. Gilbert CE, Wood M, Waddell K, Foster A. Causes of childhood blindness in east Africa: results in 491 pupils attending 17 schools for the blind in Malawi, Kenya and Uganda. *Ophthalmic Epidemiol.* 1995; 2:77-84.
11. Kawuma M, Mayeku R. A survey of prevalence of refractive errors among children in lower primary schools in Kampala district. *Afr Health Sci.* 2002; 2:69-72.
12. Msukwa G, Njuguna M, Tumwesigye C, Shilio B, Courtright P, Lewallen S. Cataract in children attending schools for the blind and resource centres in eastern Africa. *Ophthalmology.* 2009;116: 1009-1012.
13. Mukhtar AU, Kagame K. Pathological study of retinoblastoma in Mbarara, Uganda. *Cent Ali J Med.* 2000; 46:13-6.
14. Njuguna M, Msukwa G, Shilio B, Tumwesigye C, Courtright P, Lewallen S. Causes of severe visual impairment and blindness in children in schools for the blind in eastern Africa: changes in the last 14 years. *Ophthalmic Epidemiol.* 2009;16:151-55.
15. Silver J, Gilbert CE, Spoerer P, Foster A. Low vision in east African blind school students: need for optical low vision services. *Br J Ophthalmol.* 1995; 79:814-20.
16. Tumwesigye C, Msukwa G, Njuguna M, Shilio B, Courtright P. Inappropriate enrolment of children in schools for the visually impaired in east Africa. *Ann Trop Paediat.* 2009;29:135-39.
17. Waddell KM. Childhood blindness and low vision in Uganda. *Eye.* 1998; 12:184-92. Royal College of Ophthalmologists.
18. Waddell KM, Kagame K, Ndamira A, Twinamasiko A, Picton SV, Simmons IG, Revill P, Johnston WT, Newton R. Improving survival of retinoblastoma in Uganda. *Br J Ophthalmol.* 2015; 99(7):937-42.

Glaucoma

19. Sale MM, Fitzgerald LM, Kagame K, Erdmann I, Craig JE, Dickinson JL, Cooper RL. Investigation of the prevalence of the myocilin Q368STOP mutation in Ugandan glaucoma patients. *Ophthalmic Genet.* 2002; 23:67-9.

HIV/AIDS

20. Ateenyi-Agaba C. Conjunctiva squamous cell carcinoma associated with HIV infection in Kampala, Uganda. *Lancet.* 1995; 345:695-6.
21. Ateenyi-Agaba C, Dai M, Le Calvez F, Katongole-Mbidde E, Smet A, Tommasino M, Franceschi S, Hainaut P, Weiderpass E. TP53 mutations in squamous-cell carcinomas of the conjunctiva: evidence for UV-induced mutagenesis. *Mutagenesis.* 2004; 19:399-401.

22. Ateenyi-Agaba C, Franceschi S, Wabwire-Mangen F, Arslan A, Othieno E, Binta-Kahwa J. Human papillomavirus infection and squamous cell carcinoma of the conjunctiva. *Br J Cancer*. 2010;102:262-67.
23. Morgan D, Jones C, Whitworth J, Ross A, Johnson G. Ocular findings in HIV-1 negative participants in a rural population-based cohort in Uganda. *Int Ophthalmol*. 1998; 22:183-92.
24. Newton R, Ferlay J, Reeves G, Beral V, Parkin DM. Effect of ambient solar ultraviolet radiation on incidence of squamous-cell carcinoma of the eye. *Lancet*. 1996; 347:1450-1.
25. Newton R, Ziegler J, Ateenyi-Agaba C, Bousarghin L, Casabonne D, Beral V, Mbidde E, Carpenter L, Reeves G, Parkin DM, Wabinga H, Mbulaiteye S, Jaffer J, Bourbouli D, Boshoff C. The epidemiology of conjunctival squamous cell carcinoma in Uganda. *Br J Cancer*: 2002; 87: 301-8.
26. Okongo M, Morgan D, Mayanja B, Ross A, Whitworth J. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. *Int J Epidemiol*. 1998; 27: 698-702.
27. Otiti-Sengeri J, Colebunders R, Kempen JH, Ronald A, Sande M, Katabira E. The Prevalence and Causes of Visual Loss Among HIV-infected Individuals with Visual Loss in Uganda. *J Acquir Immune Defic Syndr*. 2009. [Epub].
28. Thomas OJ. Acquired Immunodeficiency Syndrome-Associated Cancers in Sub-Saharan Africa. *Seminars in Oncology*, vol 28, no 2; April, 2000: pp 198-206.
29. Tornesello ML, Duraturo ML, Waddell KM, Biryahwalo B, Downing R, Lucas SB, Gian U, Buonaguro L, Buonaguro FM. TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda. *Cancer Detect Prev*. 2005; 29(6): 501-8.
30. Waddell KM, Downing RG, Lucas SB, Newton R. Corneo-conjunctival carcinoma in Uganda. *Eye*. 2006; 20(8): 893-9.
31. Waddell K, Kwehangana J, Johnston WT, Lucas S, Newton R. A case-control study of ocular surface squamous neoplasia (OSSN) in Uganda. *Int J Cancer*. 2010;127(2):427-32.
32. Waddell KM, Lewallen S, Lucas SB, Ateenyi-Agaba C, Herrington CS, Liomba G. Carcinoma of the conjunctiva and HIV infection in Uganda and Malawi. *Br J Ophthalmol*. 1996; 80:503-8.
33. Waddell KM, Lucas SB, Downing RG. Case report and small case series: conjunctival cryptococcosis in the acquired immunodeficiency syndrome. *Arch Ophthalmol*. 2000; 118(10): 1452-3.
34. Waddell K, Magyezi J, Bousarghin L, Coursaget P, Lucas S, Downing R, Casabonne D, Newton R. Antibodies against human papillomavirus type 16 (HPV-16) and conjunctival squamous cell neoplasia in Uganda. *Br J Cancer*. 2003; 88(12); 2002-3.

Injuries

35. Asaria J, Kobusingwe OC, Khingi BA, Balikuddembe R, Gomez M, Beveridge M. Acid burns from personal assault in Uganda. *Burns*. 2004; 30: 78-81.

Leprosy

36. Waddell KM. Intraocular lens implantation for cataract following leprosy. *Lepr Rev*. 1999; 70:74-5.
37. Waddell KM. The 22nd Kellersberger Memorial Lecture, 1997. Preventing loss of sight from leprosy. *Ethiop Med J*. 1997; 35:263-70.
38. Waddell KM, Saunderson PR. Is leprosy blindness avoidable? The effect of disease type, duration, and treatment on eye damage from leprosy in Uganda. *Ophthalmology*. 1995; 79: 250-56.

Malaria

39. Idro R, Kakooza-Mwesige A, Balyejussa S, Mirembe G, Mugasha C, Tugumisirize J, Byarugaba J. Severe neurological sequelae and behavior problems after cerebral malaria in Ugandan children. *BMC Research Notes* 2010; 3: 104.
40. Mwanga-Amumpaire J, Ndeezi G, Tumwine JK. Effect of vitamin A adjunct therapy for cerebral malaria in children admitted to Mulago hospital: a randomized controlled trial. *Afr Health Sci*. 2012; 12(2): 90-7.
41. Villaverde, C., et al. Comparison of Retinopathy-Positive and Retinopathy-Negative Cerebral Malaria. *Am J Trop Med Hyg*. 2017; 96(5): 1176-1184.
42. Waddell KM. Eye damage from chloroquine as an antimalarial: misuse make safe medicine unsafe. *Trop Doct*. 1997; 27:10-12.

Onchocerciasis

43. Amazigo UV, Obono M, Dadzie KY, Remme J, Jiva J, Ndyomugenyi R, ROUNGOU JB, Noma M, Seketeli A. Monitoring community-directed treatment programmes for sustainability: lessons from the African Programme for Onchocerciasis Control (APOC). *Ann Trop Med Parasitol*. 2002; 96:75-92.
44. Babalola OE, Ogbuagu FK, Maegga BT, Braide EI, Magimbi C, Zoure H, Yameogo L, Seketeh A. African programme for onchocerciasis control: ophthalmological findings in Bushenyi, Uganda. *West Afr J Med*. 2011; 30(2): 104-9.
45. Babalola OE, Umeh RE, Mahmoud AO. Computerized motion sensitivity screening tests in a multicountry rural onchocercal community survey in Africa. *Middle East Afr J Ophthalmol*. 2010; 17(4): 320-4.
46. Brieger WR, Okeibunor JC, Abiose AO, Ndyomugenyi R, Wanji S, Elhassan E, Amazigo UV. Characteristics of persons who complied with and failed to comply with annual ivermectin treatment. *Trop Med Int Health*. 2012; 17(7): 920-30.
47. CDI Study Group. Community-directed interventions for priority health problems in Africa: results of a multicountry study. *Bull World Health Organ* 2010;88:509-518.

48. Cheke RA, Garms R. Indices of onchocerciasis transmission by different members of the *Simulium damnosum* complex conflict with the paradigm of forest and savanna parasite strains. *Acta Trop.* 2013; 125(1): 43-52.
49. Kaiser C, Asaba G, Kasoro S, Rubaale T, Kabagambe G, Mbazazi M. Mortality from epilepsy in an onchocerciasis – endemic area in West Uganda. *Trans R Soc Trop Med Hyg.* 2007; 101(1): 48-55.
50. Kaiser C, Pion SD, Boussinesq M. Case-control studies on the relationship between onchocerciasis and epilepsy: a systematic review and meta-analysis. *PLoS Negl Trop Dis.* 2013; 7(3): e2147.
51. Kaiser C, Rubaale T, Tukesiga E, Kipp W, Kabagambe G, Ojony JO, Asaba G. Association between onchocerciasis and epilepsy in the Itwara hyperendemic focus. West Uganda: controlling for time and intensity of exposure. *Am J Trop Med Hyg.* 2011; 85(2): 225-8.
52. Katarbarwa M, Eyamba A, Habomugisha P, Lakwo T, Ekobo S, Kamgno J. After a decade of annual dose mass ivermectin treatment in Cameroon and Uganda, onchocerciasis transmission continues. *Trop Med Intern Health.* 2008;13:1196-1203.
53. Katarbarwa M, Habomugisha P, Eyamba A, Agunyo S, Mentou C. Monitoring ivermectin distributors involved in integrated health care services through community-directed interventions—a comparison of Cameroon and Uganda experiences over a period of three years (2004-2006). *Trop Med Int Health.* 2010;15(2):216-23.
54. Katarbarwa M, Lakwo T, Habumogisha P, Richards F, Eberhard M. Short Report: Could Neurocysticercosis Be Cause of “Onchocerciasis-Associated” Epileptic Seizures? *Am J Trop Med Hyg.* 2008;78(3):400-401.
55. Katarbarwa MN, Habomugisha P, Agunyo S. Involvement and performance of women in community-directed treatment with ivermectin for onchocerciasis control in Rukungiri district, Uganda. *Health Soc Care Community.* 2002; 10:382-93.
56. Katarbarwa MN, Habomugisha P, Agunyo S, McKelvey AC, Ogweng N, Kwebiiha S, Byenume F, Male B, McFarland D. Traditional kinship system enhanced classic community-directed treatment with ivermectin (CDTI) for onchocerciasis control in Uganda. *Trans R Soc Trop Med Hyg.* 2010;104(4): 265-72.
57. Katarbarwa MN, Habomugisha P, Richards FO. Implementing community-directed treatment with ivermectin for the control of onchocerciasis in Uganda (1997-2000): an evaluation. *Ann Trop Med Parasitol.* 2002; 96:61-73.
58. Katarbarwa MN, Lakwo T, Habomugisha P, Agunyo S, Byamukama E, Oguttu D, Tukesiga E, Unoba D, Dramuke P, Onapa A, Tukahebwa EM, Lwamafa D, Walsh F, Unnasch TR. Transmission of *Onchocerca volvulus* Continues in Nyagak-Bondo Focus of Northwestern Uganda after 18 Years of a Single Dose of Annual Treatment with Ivermectin. *Am J Trop Med Hyg.* 2013; 89(2): 293-300.
59. Katarbarwa MN, Richards FO Jr, Ndyomugenyi R. In rural Ugandan communities the traditional kinship/clan system is vital to the success and sustainment of the African Programme for Onchocerciasis Control. *Ann Trop Med Parasitol.* 2000; 94:485-95.
60. Katarbarwa MN, Walsh F, Habomugisha P, Lakwo TL, Agunyo S, Oguttu DW, Unnasch TR, Unoba D, Byamukama E, Tukesiga E, Ndyomugenyi R, Richards FO.

Transmission of onchocerciasis in wadelai focus of northwestern Uganda has been interrupted and the disease eliminated. *J Parasitol Res.* 2012; 2012: 748540.

61. Katarbarwa M, Lakwo T, Habomugisha P, Agunyo S, Byamukama E, Oguttu D, Ndyomugyenyei R, Tukesiga E, Ochieng GO, Abwaimo F, Onapa A, Lwamafa DW, Walsh F, Unnasch TR, Richards FO. Transmission of *Onchocerca volvulus* by *Simulium neavei* in Mount Elgon focus of Eastern Uganda has been interrupted. *Am J Trop Med Hyg.* 2014 Jun;90(6):1159-66.
62. Katarbarwa MN, Habomugisha P, Eyamba A, Byamukama E, Nwane P, Arinaitwe A, Musigire J, Tushemereirwe R, Khainza A. Community-directed interventions are practical and effective in low-resource communities: experience of ivermectin treatment for onchocerciasis control in Cameroon and Uganda, 2004-2010. *Int Health.* 2015; 7. pii: ihv038
63. Lagoro, D. K. and D. A. Arony. Nodding syndrome (NS) and *Onchocerca Volvulus* (OV) in Northern Uganda. *Pan Afr Med J.* 2017; 28: 1.
64. Lakwo TL, Garms R, Rubaale T, Katarbarwa M, Walsh F, Habomugisha P, Oguttu D, Unnasch T, Namanya H, Tukesiga E, Katamanywa J, Bamuhiiga J, Byamukama E, Agunyo S, Richards F. The disappearance of onchocerciasis from the Itwara focus, western Uganda after elimination of the vector *Simulium neavei* and 19 years of annual ivermectin treatments. *Acta Trop.* 2013; 126(3): 218-21.
65. Luroni, L. T., et al. The interruption of *Onchocerca volvulus* and *Wuchereria bancrofti* transmission by integrated chemotherapy in the Obongi focus, North Western Uganda. *PLoS One.* 2017; 12(12): e0189306.
66. Meredith SE, Cross C, Amazigo UV. Empowering communities in combating river blindness and the role of NGOs: case studies from Cameroon, Mali, Nigeria, and Uganda. *Health Res Policy Syst.* 2012; 10:16.
67. Murdoch ME, Asuzu MC, Hagan M, Makunde WH, Ngoumou P, Ogbuagu KF, Okello D, Ozoh G, Remme J. Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa. *Ann Trop Med Parasitol.* 2002; 96:283-96.
68. Ndyomugyenyei R. Onchocerciasis control in Uganda. *World Health Forum.* 1998; 19:192-5.
69. Ndyomugyenyei R, Byamungu A, Korugyendo R. Perceptions on onchocerciasis and ivermectin treatment in rural communities in Uganda: implication for long term compliance. *Intern Health.* 2009;1:163-68.
70. Ndyomugyenyei R, Tukesiga E, Katamanywa J. Intermittent preventive treatment of malaria in pregnancy (IPTp): participation of community-directed distributors of ivermectin for onchocerciasis improves IPTp access in Ugandan rural communities. *Trans Roy Soc Trop Med Hyg.* 2009; 103: 1221-1228.
71. Oguttu D, Byamukama E, Katholi CR, Habomugisha P, Nahabwe C, Ngabirano M, Hassan HK, Lakwo T, Katarbarwa M, Richards FO, Unnasch TR. Serosurveillance to monitor onchocerciasis elimination: the Ugandan experience. *Am J Trop Med Hyg.* 2014 Feb;90(2):339-45.
72. Okeibunor JC, Amuyunzu-Nyamongo M, Onyeneho NG, Tchounkeu YF, Manianga C, Kabali AT, Leak S. Where would I be without ivermectin? Capturing the benefits of

community-directed treatment with ivermectin in Africa. *Trop Med Int Health*. 2011; 16(5): 608-21.

73. Okeibunor JC, Brieger WR, Abiose AO, Elhassan E, Ndyomugenyi R, Wanji S, Amazigo UV. Intention to continue with ivermectin treatment for onchocerciasis control after eight years of annual distribution in Cameroon, Nigeria, and Uganda. *Int Q Community Health Educ*. 2012-2013; 33(2): 159-73.
74. Ozoah GA, Murdoch ME, Bissek AC, Hagan M, Ogbuagu K, Shamad M, Braide EI, Boussinesq M, Noma MM, Murdoch IE, Seketeli A, Amazigo UV. The African Programme for Onchocerciasis Control: impact on onchocercal skin disease. *Trop Med Int Health*. 2011; 16(7): 875-83.
75. Sama MT, Homeida M, Ngang P, Liese BH, Amazigo U, Seketeli A. A multi-centre study of community-directed ivermectin distributors' (CDDs) involvement in other healthcare and development program activities in Cameroon, Togo, Sudan, Nigeria and Uganda. *Trop Doct*. 2003; 33:237-41.
76. Umeh RE, Babalolba OE, Mahmoud AO, Okoye OI, Asana UE, Umeh CN, Braide E, Biritwum R, Seketeli A. Utility and effectiveness of computerized motion sensitivity screening tests in rural onchocercal community survey. *West Afr J Med*. 2010; 29(6): 412-6.
77. Wakabi W. Worrisome outbreak of river blindness in northern Uganda. *CMAJ*. 2009; 181(1-2): E4.

Refractive Errors

78. McAlister WH, Wingert TA, Farris JC. Prevalence of ametropia in Ugandan soldiers. *Mil Med*. 2002; 167:801-2.

Other

79. Kaggwa G. Ophthalmic clinical officers: developments in Uganda. *Community Eye Health*. 2014;27(86):34.
80. Hamilton A, Richter S. Targeted survey as a method to rationalize priorities for a strategy to improve eye health in rural Uganda. *Rural Remote Health*. 2015;15:2783. Epub 2015; 20.
81. Mearkle, R., et al. Barriers to hand hygiene in ophthalmic outpatients in Uganda: a mixed methods approach. *J Ophthalmic Inflamm Infect*. 2016; 6(1): 11.